摘要
目的研究云南彝药恒古骨伤愈合剂对去势雌性大鼠骨密度的影响。方法将36只雌性SD大鼠随机平均分为对照组、手术组、给药组,每组12只。给药组和手术组大鼠行经腹双侧卵巢切除术,同时对给药组予恒古骨伤愈合剂;对照组大鼠经腹切除与卵巢重量相同的脂肪组织。术后第1周、第10周行双能射线骨密度测定,以了解其骨密度(bone mineral density,BMD)、骨矿盐含量(bone mineral conten,BMC)。术中术后10w内去势雌性大鼠无死亡情况。结果第10周给药组对比手术组,给药组全身BMD增加1.84%,差异具有统计学意义(P<0.05);给药组对比对照组,给药组全身BMD下降1.2%,但差异无统计学意义(P>0.05)。全身骨矿盐含量给药组>手术组>对照组,两两比较差异无统计学意义(P>0.05)。给药组和手术组体重相近,差异无统计学差异(P>0.05);但两组体重均大于对照组体重,且差异有显著统计学意义(P<0.01)。结论恒古骨伤愈合剂可以延缓去势雌性大鼠骨质疏松中骨量的丢失。
Objective Osteoking, China Yunnan Yi, is a local Chinese herbal medicine. It has been used to treat osteoporotic fracture, but its therapeutic effect on osteoporosis is not clear. The purpose of this experiment is to study the effects of Osteoking on ovariectomized female rat osteoporosis model. Methods Thirty-six female SD rats were randomly divided into three groups （ each group of !2 ） ： the control, the surgery and the dose groups. The dose and the surgery groups were operated with bilateral oophorectomy, and at the same time the dose group was fed with Osteoking. Bone mineral density and bone mineral salt content were measured at the first and 10th week. Results At 10 weeks the total BMD of the dose group was significantly higher than that of the surgery group （by 1.84% , P 〈0.05）. The total BMD of the dose group was 1.2% lower than the control group, which did not reach statistical significance （P 〉 0. 05 ）. For total BMC： the dose 〉 the surgery 〉 the control. The body weight of the dose group was similar to that of the surgery group, with no significant difference （ P 〉 0. 05 ）. The body weight of both dose and surgery groups was significantly heavier than that of the control group （ P 〈 0. 05 ）. Conclusion Osteoking could reduce the loss of bone mass in ovariectomized female rat model of osteoporosis.
出处
《中国骨质疏松杂志》
CAS
CSCD
北大核心
2016年第12期1513-1515,1539,共3页
Chinese Journal of Osteoporosis
基金
国家自然科学基金委员会-云南省人民政府联合基金项目(U1502227)
关键词
中医中药
恒古骨伤愈合剂
骨质疏松
骨密度
骨矿盐含量
Traditional Chinese Medicine
Osteoking
Osteoporosis
Bone mineral density
Bone mineral content
